● Goal · all research areas
Metabolic & weight research
These compounds appear in the metabolic & weight research literature. This page reports what is studied and what it costs — it is not a claim that anything works, is safe, or is for human use.
● Human trial data
What the published trials report
- Retatrutide ~24% mean weight loss phase-2 trial, 48 weeks · PMID 37366315
- Tirzepatide ~20% mean weight loss phase-3, head-to-head vs semaglutide · PMID 40353578
- Semaglutide ~14% mean weight loss phase-3, head-to-head vs tirzepatide · PMID 40353578
- Cagrilintide ~10% alone (~22% combined as CagriSema) phase-2 · PMID 34798060
Figures are mean weight reduction reported in each drug's trial. Retatrutide's is a phase-2 result; the tirzepatide and semaglutide figures are from a head-to-head phase-3 trial. Trials differ in size and length, so cross-comparisons are approximate — not a recommendation, and not a claim any of this applies to you.
● Compounds in this literature
7 with live prices
Ordered by evidence strength, then price.
Strong evidence
Tirzepatide
GLP-1 / GIP dual agonist
$1.35/mg 39 vendors
Strong evidence
Semaglutide
GLP-1 agonist
$1.70/mg 29 vendors
Strong evidence
Tesamorelin
Growth-hormone secretagogue
$3.80/mg 83 vendors
Moderate evidence
Retatrutide
GLP-1 / triple agonist
$2.02/mg 40 vendors
Moderate evidence
Cagrilintide
Amylin analog
$4.60/mg 48 vendors
Limited evidence
AOD-9604
Metabolic peptide
$4.58/mg 68 vendors
Preclinical only
MOTS-c
Mitochondrial peptide
$1.30/mg 99 vendors
● Ask pepmg
Questions this area raises
All products listed are sold by third-party vendors for laboratory and research use only (RUO). pepmg sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Listings are price-tracking data, not endorsements.